Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share starting with the February 16, 2027 payment. The stronger outlook rests on…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised 2026 guidance and higher dividend are positive factors for this large pharma stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b.
- 02The company raised full year revenue and adjusted EPS guidance.
- 03The quarterly dividend rises 5.2% to US$1.82 per share.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets